Evaluation of anticonvulsant activity of Bixa Orellana Linn. seed
Abstract
Introduction: Epilepsy is a neurological disorder with recurrent seizures, often inadequately controlled by existing medications. Despite the availability of antiepileptic drugs, many patients experience inadequate seizure control and adverse effects, prompting the exploration of alternative treatments. Bixa orellana Linn., known as Annatto or Achiote, has traditional use for seizures. Objective: This study explored the anticonvulsant properties of Bixa orellana Linn. seed extract using animal models.
Method: The extract was then tested in animal models, including the maximal electroshock seizure (MES) and Pentylenetetrazole (PTZ) models.
Results and Discussion: The extract exhibited significant anticonvulsant activity in both the maximal electroshock seizure (MES) and Pentylenetetrazole (PTZ) models. It delayed clonus onset, reduced the duration of the tonic extensor phase, and provided 100% protection against convulsions at medium and high doses in the MES model. In the PTZ model, it increased convulsion latency and offered high protection. Bixa orellana Linn. seeds show promise as a natural antiepileptic agent, warranting further research for mechanistic understanding and identification of bioactive compounds.
Conclusion: Developing new antiepileptic drugs from natural sources like Bixa orellana Linn. could offer alternative treatment options for epilepsy.
Downloads
References
Anwar, H., Khan, Q. U., Nadeem, N., Pervaiz, I., Ali, M., & Cheema, F. F. (2020). Epileptic seizures. Discoveries, 8(2), e110.
Castel-Branco, M. M., Alves, G. L., Figueiredo, I. V., Falcão, A., & Caramona, M. M. (2009). The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods and findings in experimental and clinical pharmacology, 31(2), 101-106.
Chinedu, E., Arome, D., & Solomon Ameh, F. (2013). A new method for determining acute toxicity in animal models. Toxicology international, 20(3).
Goldenberg, M. M. (2010). Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. Pharmacy and Therapeutics, 35(7), 392.
Hanaya, R., & Arita, K. (2016). The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications. Neurologia medico-chirurgica, 56(5), 205–220.
Löscher, W., & Klein, P. (2021). The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs, 35(9), 935–963.
Manchishi, S. M. (2017). Recent Advances in Antiepileptic Herbal Medicine. Current Neuropharmacology, 16(1).
Raddatz-Mota, D., Pérez-Flores, L. J., Carrari, F., Mendoza-Espinoza, J. A., de León-Sánchez, F. D., Pinzón-López, L. L., ... & Rivera-Cabrera, F. (2017). Achiote (Bixa orellana L.): a natural source of pigment and vitamin E. Journal of food science and technology, 54, 1729-1741.
Rogawski, M. A. (2006). Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy research, 69(3), 273-294.
Shimada, T., & Yamagata, K. (2018). Pentylenetetrazole-induced kindling mouse model. JoVE (Journal of Visualized Experiments), (136), e56573.
Shiriki, D., Ubwa, S. T., Ubwa, S. T., Yusufu, M. I., & Shambe, T. (2019). Extraction methods and inhibition studies of ten plant extracts on nine yam rot pathogenic microorganisms. Food and Nutrition Sciences, 10(04), 439.
Sirven, J. I. (2015). Epilepsy: a spectrum disorder. Cold Spring Harbor perspectives in medicine, 5(9), a022848.
Raddatz-Mota, D., Pérez-Flores, L. J., Carrari, F., Mendoza-Espinoza, J. A., de León-Sánchez, F. D., Pinzón-López, L. L., Godoy-Hernández, G., & Rivera-Cabrera, F. (2017). Achiote (Bixa orellana L.): a natural source of pigment and vitamin E. Journal of Food Science and Technology, 54(6), 1729–1741.
Wahab, A. (2010). Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development. Pharmaceuticals, 3(7), 2090–2110.
Copyright (c) 2023 Ramdas Bhat, Preeti Shanbhag
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
